The combined company will operate as Cotiviti, offering clients analytic insights, market expertise and high-performance services.
Per the terms of the agreement, Cotiviti shareholders will receive $44.75 in cash for each share of Cotiviti common stock they hold. The transaction was announced June 19 and received approval from shareholders on Aug. 24. Emad Rizk, MD, current president and CEO of Verscend, will retain the titles for the combined business.
Verscend Technologies is a portfolio company of Veritas Capital, which recently acquired GE Healthcare’s ValueBased Care Division.
More articles on health IT:
Cerner, Duke collaborate on cardiac risk app
Ochsner Health System earns HIMSS Davies Enterprise Award
Top value-based care IT consultants, according to Black Book
